Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Cal Gary who wrote (7890)	10/25/2001 3:11:41 AM
From: Cal Gary	Read Replies (1) \| Respond to of 14101

Hi Guys, sorry to go off in a tangent. Its filler time. Globe says Lorus pancreatic cancer study moves forward Lorus Therapeutics Inc LOR Shares issued 140,247,667 Oct 9 2001 close $1.010 Wednesday Oct 10 2001 In the News The Globe and Mail reports in its Wednesday, Oct. 10, edition that an unnamed industry analyst says while he is pleased to see the marketing agreement between Lorus Therapeutics and F.H. Faulding & Co., "my concern is that they're spending so much time on melanoma in Mexico when the potential for Virulizin to treat pancreatic cancer is enormous." The Globe's Leonard Zehr writes that Lorus is preparing to begin a $12-million (Canadian) late-stage test of Virulizin in patients with pancreatic cancer, which represents an annual $400-million (U.S.) market. It also is holding talks with pharmaceutical companies to distribute the drug, which could be on the market in 2004. (c) Copyright 2001 Canjex Publishing Ltd. canada-stockwatch.com How do you guys interpret the phrase "potential for Virulizin to treat pancreatic cancer is enormous"? 1. the drug's potential is to treat pancreatic cancer positively is enormous? 2. the potential to grab market share of an annual $400 million US market is enormous? If the latter, I wonder what this unnamed industry analyst may refer to a market that is $5 to $12 Billion in size? Can't be enormous. Gotta be "bigger than huge", gigantic, colossal, .... Help me out. Also note that in less than a year LOR has about doubled its number of shares outstanding. DMX is diluting somewhat at this time, but at a much much better rate than LOR. BTW, another Trivia to show how under valued DMX is: QLT appears to be on course to make $250mm revenue this fiscal year. Currently YTD revenues are about $250mm. They have a complicated (to me) revenue and net income sharing agreement with Novartis. I think projected net income will come in at about $0.63 per share this fiscal year. Or about 60 times P/E!! I'm still trying to figure out how large their market is and its expected growth rate. Unlike OA which doesn't go away (unless a cure happens), QLT's Visudyne will "need a fresh supply" of new patients every year to treat. That is, if I understand correctly that Visudyne is a "cure." QLT's real reason for existance is its photo activate drug delivery system, like DMX's non-systematic transdermal drug delivery system.